Recon: FDA Approves Novartis Combo Therapy

• FDA approves Novartis combo therapy for aggressive type of thyroid cancer (Reuters)
• Jury convicts four in CMS-Deerfield insider trading case (Mass Device)
• Ex-Valeant Official Sought ‘Big Payday’ in Bribe Scam, Jury Told (Bloomberg)
• Federal kickback law might be used to bring down drug prices, FDA commissioner suggests (Stat)
• Sarepta adds muscular dystrophy gene therapies via Myonexus pact (Fierce)
• HHS To Brief Congressional Staff On Drug Prices Friday (IHP-$)

• China’s CDH Investments counters Varian with unsolicited $1.4B bid for Sirtex (Mass Device)
• European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure (EMA)
• Notice: Medical Device Single Audit Program (MDSAP) Reduction of Audit Times for Small-sized Enterprises – update (Health Canada)

• Merck invests in Moderna (PharmaTimes) (C&EN) (Forbes)
• Celgene's timeline for refiling ozanimod gets mixed reviews (BioPharma Dive) (Press)
• OGD Updates March 2018 Statistics (Lachman Consultants)
• Interleukin-6: designing specific therapeutics for a complex cytokine (Nature Reviews Drug Discovery)
• For shame: ‘Pharma Bro’ Shkreli is in prison, but Daraprim’s price is still high (Kaiser Health News)
• Gottlieb Tackles Tough Issues in First Year at FDA (BioPharm International)

• Post-exposure treatments for Ebola and Marburg virus infections (Nature Reviews Drug Discovery)
• Bio Roundup: IDO Fallout, Express Scripts Dumps Amgen, Isaly Out & More (Xconomy)
• ICER Weekly Review (ICER)

• Class 2 Device Recall cobas b 2216Roche OMNI S6 system (FDA)

• Dem senators urge FDA to remove powerful opioids from the market (The Hill)

• FDA Advisory Committee Calendar

• Advertising investigations: April 2018 (MHRA)

• The best medicine? What’s meaningful for our patients (NY Times-$)